Literature DB >> 17371827

In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.

M N Brunelle1, J Lucifora, J Neyts, S Villet, A Holy, C Trepo, F Zoulim.   

Abstract

The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17371827      PMCID： PMC1891401          DOI： 10.1128/AAC.01440-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Antiviral therapy of chronic hepatitis B.

Authors:  Fabien Zoulim
Journal:  Antiviral Res       Date:  2006-04-25       Impact factor: 5.970

2.  Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.

Authors:  Florian van Bömmel; Bernhard Zöllner; Christoph Sarrazin; Ulrich Spengler; Dietrich Hüppe; Bernd Möller; Heinz-Hubert Feucht; Bertram Wiedenmann; Thomas Berg
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

3.  Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.

Authors:  Karine Lacombe; Joël Gozlan; Pierre-Yves Boelle; Lawrence Serfaty; Fabien Zoulim; Alain-Jacques Valleron; Pierre-Marie Girard
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

4.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.

Authors:  Scott K Fung; Pietro Andreone; Steve H Han; K Rajender Reddy; Arie Regev; Emmet B Keeffe; Munira Hussain; Carmela Cursaro; Pamela Richtmyer; Jorge A Marrero; Anna S F Lok
Journal:  J Hepatol       Date:  2005-07-07       Impact factor: 25.083

5.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Sarah Arterburn; Shelly Xiong; Graeme Currie; Carol L Brosgart
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

6.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Patrick Marcellin; Ting-Tsung Chang; Seng Gee Lim; Myron J Tong; William Sievert; Mitchell L Shiffman; Lennox Jeffers; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

7.  A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.

Authors:  F Zoulim; T Poynard; F Degos; A Slama; A El Hasnaoui; P Blin; F Mercier; P Deny; P Landais; P Parvaz; C Trepo
Journal:  J Viral Hepat       Date:  2006-04       Impact factor: 3.728

8.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

Authors:  Peter Angus; Rhys Vaughan; Shelly Xiong; Huiling Yang; William Delaney; Craig Gibbs; Carol Brosgart; Danielle Colledge; Rosalind Edwards; Anna Ayres; Angeline Bartholomeusz; Stephen Locarnini
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

9.  Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates.

Authors:  J Balzarini; C Pannecouque; E De Clercq; S Aquaro; C-F Perno; H Egberink; A Holý
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

10.  Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant.

Authors:  Vlad Ratziu; Vincent Thibault; Yves Benhamou; Thierry Poynard
Journal:  Comp Hepatol       Date:  2006-01-11
View more
  11 in total

1.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

2.  Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.

Authors:  Bulent Baran; Ozlem Mutluay Soyer; Asli Cifcibasi Ormeci; Suut Gokturk; Sami Evirgen; Hamza Ugur Bozbey; Filiz Akyuz; Cetin Karaca; Kadir Demir; Fatih Besisik; Derya Onel; Mine Gulluoglu; Selim Badur; Sabahattin Kaymakoglu
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

3.  2-[(4-Chloro-benz-yl)sulfan-yl]-4-(2-methyl-prop-yl)-6-(phenyl-sulfan-yl)pyrimidine-5-carbonitrile.

Authors:  Ali A El-Emam; Omar A Al-Deeb; Abdulghafoor A Al-Turkistani; Seik Weng Ng; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-06-13

4.  New approaches in the management of chronic hepatitis B: role of tenofovir.

Authors:  Jurriën Gp Reijnders; Harry LA Janssen
Journal:  Infect Drug Resist       Date:  2009-04-24       Impact factor: 4.003

5.  6-(2-Methyl-prop-yl)-4-oxo-2-sulfanyl-idene-1,2,3,4-tetra-hydro-pyrimidine-5-carbonitrile.

Authors:  Omar A Al-Deeb; Ali A El-Emam; Abdulghafoor A Al-Turkistani; Seik Weng Ng; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-02-10

6.  2-[(4-Chloro-benz-yl)sulfanyl]-4-(2-methyl-prop-yl)-6-[3-(trifluoro-meth-yl)anilino]-pyrimidine-5-carbonitrile.

Authors:  Ali A El-Emam; Omar A Al-Deeb; Nasser R El-Brollosy; Seik Weng Ng; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-06-13

7.  Resistance mutations of hepatitis B virus in entecavir-refractory patients.

Authors:  Norie Yamada; Ryuichi Sugiyama; Sayuri Nitta; Asako Murayama; Minoru Kobayashi; Chiaki Okuse; Michihiro Suzuki; Kiyomi Yasuda; Hiroshi Yotsuyanagi; Kyoji Moriya; Kazuhiko Koike; Takaji Wakita; Takanobu Kato
Journal:  Hepatol Commun       Date:  2017-03-09

8.  In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.

Authors:  Yu-Bing Zhou; Ya-Feng Wang; Yan Zhang; Li-Yun Zheng; Xiao-Ang Yang; Ning Wang; Jin-Hua Jiang; Fang Ma; De-Tao Yin; Chang-Yu Sun; Qing-Duan Wang
Journal:  Eur J Pharmacol       Date:  2012-02-24       Impact factor: 4.432

9.  Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.

Authors:  Ann W Walsh; David R Langley; Richard J Colonno; Daniel J Tenney
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

10.  Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study.

Authors:  Manuel Rodríguez; Juan Manuel Pascasio; Enrique Fraga; Javier Fuentes; Martín Prieto; Gloria Sánchez-Antolín; José Luis Calleja; Esther Molina; María Luisa García-Buey; María Ángeles Blanco; Javier Salmerón; María Lucía Bonet; José Antonio Pons; José Manuel González; Miguel Ángel Casado; Francisco Jorquera
Journal:  World J Gastroenterol       Date:  2017-11-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.